Abstract Library

#4567 Malignant pheochromocytoma with late distant metastases and secondary hypercalcaemia

Introduction: Pheochromocytoma is a rare neuroendocrine tumour of the adrenal medulla. Malignant variants occur with a very low frequency and can be diagnosed only after the spread of distant metastasis.

Conference:

Presenting Author:

Authors: Kirova I, Vandeva S, Markova M, Elenkova A, Robeva R,

Keywords: neuroendocrine, malignant pheochromocytoma, metastasis, hypercalcaemia,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#3869 Sunitinib for the treatment of advanced pheochromocytomas/paragangliomas – A phase 2 clinical trial

Introduction: Malignant pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with limited treatment options. Here, we report the preliminary results of SUTNET trial assessing safety and efficacy of sunitinib in advanced/unresectable PPGLs.

Conference:

Presenting Author: Prinzi N

Authors: Prinzi N, Corti F, Capone I, Perrone F, Tamborini E,

Keywords: pheochromocytoma, paraganglioma, sunitinib, neuroendocrine,

#3769 Adrenal neuroendocrine tumors in Oran – Epidemiology and survival

Introduction: Pheochromocytomas (PCC) are rare neuroendocrine tumors with a prevalence of 1/10000 in the general population. They are sporadic in 80% of cases, family forms are found in 10 to 20% of cases. PCCs represent 60% of multiple endocrine neoplasia type 2. They occur at any age with a peak between 30 and 50 years old. The clinical symptomatology dominated by arterial hypertension is linked to the hypersecretion of catecholamines. Metastases are common in the liver, bone or lung. The 5-year survival of malignant pheochromocytomas is less than 50%.

Conference:

Presenting Author:

Authors: Boumansour N, Khalifa S, Kehili H, Bengueddache A,

Keywords: adrenals, Neuroendocrine tumor, Pheochromocytoma, epidemiology, survival,

#3478 Peptide Receptor Radionuclide Therapy with 177Lutethium or 90Yttrium- DOTA-TATE or –TOC in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a single institutional retrospective analysis

Introduction: Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumors and limited systemic therapies are available so far.

Conference:

Presenting Author: Rubino M

Authors: Rubino M, Di Stasio G, Spada F, Rocca P, Laffi A,

Keywords: Pheochromocytoma, Paraganglioma, Peptide Receptor Radionuclide Therapy, 90Y, 177Lu,